InvestorsHub Logo
Followers 81
Posts 3648
Boards Moderated 0
Alias Born 02/15/2010

Re: JB3729 post# 72539

Friday, 08/05/2016 10:14:27 AM

Friday, August 05, 2016 10:14:27 AM

Post# of 469760
Why I believe that the 2a trial is benefitting a high % of patients -

7/22/15 - ANAVEX 2-73 showed in 83 percent (10/12) of patients positive cognitive effects during PART A of the study, which consists of a 36-day on-off-on not-yet-optimized dosing regimen to assess bioavailability.

11/9/2015 - In a preliminary interim readout of PART B data, ANAVEX 2-73 improved ADCS-ADL score, a functional measurement, over a period of 12 weeks by +3.21 over baseline, with 11 out of 14 (78.6%) patients improving.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News